Literature DB >> 16041601

No correlation between the p38 MAPK pathway and the contractile dysfunction in diabetic cardiomyocytes: hyperglycaemia-induced signalling and contractile function.

Sibylle Wenzel1, Golozar Soltanpour, Klaus-Dieter Schlüter.   

Abstract

Besides the classical cardiovascular diseases, high levels of blood glucose directly interfere with cardiomyocytes. The mechanisms responsible for this have not yet been explored in detail. This study aims to determine if hyperglycaemia has any impact on prominent signalling molecules and on the contractile function of cardiomyocytes. Freshly isolated cardiomyocytes from adult rats were treated with various concentrations of glucose. Formed free radicals were measured by DCF-fluorescence. TGFbeta expression and p38 MAP-kinase (MAPK) activation were measured by Western blotting. The contractile efficiency was determined by measurement of the maximal amount of cell shortening. Glucose (30 mM) caused an increase in formation of radicals, phosphorylation of p38 MAPK, and TGFbeta expression. Under conditions of low viscosity (1 cp), contractile responses to hyperglycaemia (15 mM) were not altered in contrast to control. However, enhancement of viscosity (400 cp) effected a limitation of contractile function. The responsiveness to beta-adrenoceptor stimulation did not change. Neither inhibition of p38 MAPK with SB 202190 (1 microM) nor inhibition of reactive oxygen species with vitamin C did alter these measured functional parameters. Diabetes mellitus directly influences the activation degree of prominent signalling molecules and the contractile function of adult ventricular cardiomyocytes, which results in facilitating in the development of diabetic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041601     DOI: 10.1007/s00424-005-1476-5

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  30 in total

1.  Clinical and morphological features of human hypertensive-diabetic cardiomyopathy.

Authors:  S M Factor; T Minase; E H Sonnenblick
Journal:  Am Heart J       Date:  1980-04       Impact factor: 4.749

Review 2.  Troponin I, cardiac diastolic dysfunction and restrictive cardiomyopathy.

Authors:  Xu-pei Huang; Jian-feng Du
Journal:  Acta Pharmacol Sin       Date:  2004-12       Impact factor: 6.150

Review 3.  [Diabetes mellitus, left ventricular dysfunction and congestive heart failure].

Authors:  Luigi Tarantini; Andrea Di Lenarda; Mario Velussi; Pompilio Faggiano; Marco Comaschi; Ezio Faglia; Aldo Pietro Maggioni
Journal:  Ital Heart J Suppl       Date:  2004-08

4.  AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase.

Authors:  Jamie R Privratsky; Loren E Wold; James R Sowers; Mark T Quinn; Jun Ren
Journal:  Hypertension       Date:  2003-07-07       Impact factor: 10.190

Review 5.  Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications.

Authors:  Zhi You Fang; Johannes B Prins; Thomas H Marwick
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

6.  Cardiac contractile dysfunction in J2N-k cardiomyopathic hamsters is associated with impaired SR function and regulation.

Authors:  Andrea P Babick; Elliott J F Cantor; John T Babick; Nobuakira Takeda; Naranjan S Dhalla; Thomas Netticadan
Journal:  Am J Physiol Cell Physiol       Date:  2004-06-30       Impact factor: 4.249

7.  Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats.

Authors:  Laura Raimondi; Petra De Paoli; Edoardo Mannucci; Giuseppe Lonardo; Laura Sartiani; Grazia Banchelli; Renato Pirisino; Alessandro Mugelli; Elisabetta Cerbai
Journal:  Diabetes       Date:  2004-07       Impact factor: 9.461

8.  Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein.

Authors:  P Christian Schulze; Jun Yoshioka; Tomosaburo Takahashi; Zhiheng He; George L King; Richard T Lee
Journal:  J Biol Chem       Date:  2004-05-05       Impact factor: 5.157

9.  Transgenic overexpression of insulin-like growth factor I prevents streptozotocin-induced cardiac contractile dysfunction and beta-adrenergic response in ventricular myocytes.

Authors:  F L Norby; N S Aberle; J Kajstura; P Anversa; J Ren
Journal:  J Endocrinol       Date:  2004-01       Impact factor: 4.286

10.  Mitogen-activated protein kinases in the acute diabetic myocardium.

Authors:  Monika Strniskova; Miroslav Barancik; Jan Neckar; Tanya Ravingerova
Journal:  Mol Cell Biochem       Date:  2003-07       Impact factor: 3.396

View more
  3 in total

1.  Altered expression and activation of mitogen-activated protein kinases in diabetic heart during cardioplegic arrest and cardiopulmonary bypass.

Authors:  Jun Feng; Yuhong Liu; Nikola Dobrilovic; Arun K Singh; Ashraf A Sabe; Yingjie Guan; Cesario Bianchi; Frank W Sellke
Journal:  Surgery       Date:  2013-09       Impact factor: 3.982

Review 2.  Protein Kinases as Drug Development Targets for Heart Disease Therapy.

Authors:  Naranjan S Dhalla; Alison L Müller
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-05

Review 3.  Expression and Signaling of β-Adrenoceptor Subtypes in the Diabetic Heart.

Authors:  Betul R Erdogan; Martin C Michel; Ebru Arioglu-Inan
Journal:  Cells       Date:  2020-11-26       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.